Peptides for immune function and chronic infection — what research has explored

Conventional immunology is built around acute interventions: vaccines, antibiotics, antivirals, treatments for specific autoimmune diseases, cancer immunotherapy. What it doesn't have a clean toolkit for is the middle territory — the immune system that's persistently dysregulated without a diagnosable disease, the pattern of recurrent infections that doesn't quite meet clinical thresholds, the post-infectious state that standard labs don't fully capture. That gap is where immune-modulating peptides have generated significant clinical interest, particularly in integrative and functional medicine settings.

The thymic peptide family is the oldest and most extensively studied in this landscape. The thymus gland — a small organ behind the sternum that most people have never thought about — is the site of T-cell maturation. Naive T cells migrate from bone marrow to the thymus, where they're educated to distinguish self from non-self, trained into their various functional subtypes, and sent into circulation as a functioning immune force. The thymus involutes with age: it reaches its maximum size around puberty and then slowly shrinks and is replaced by fat. By middle age, thymic output is a fraction of what it was in youth. The immune system ages partly because the organ that trains it stops working as well.

Thymosin Alpha-1, often abbreviated Tα1, is the most clinically developed of the thymic peptides. It's a 28-amino-acid peptide originally isolated from thymic tissue by Allan Goldstein's group at George Washington University in the 1970s. Tα1 has regulatory approval in more than thirty countries — primarily in Asia, Eastern Europe, and Latin America — for indications including hepatitis B, hepatitis C, and use as an immunostimulant in cancer patients and immunocompromised individuals receiving chemotherapy. In Italy, it has been approved and used for decades in clinical oncology settings. The mechanism involves dendritic cell activation, T-helper cell differentiation (particularly toward Th1 responses, which are important in antiviral and anticancer immunity), and modulation of inflammatory cytokine profiles. In the United States, Tα1 is not FDA-approved as a drug but is available as a compounded peptide.

The COVID-19 pandemic generated a surge of interest in Tα1 specifically. Several clinical studies in China and Italy explored it as an adjunctive treatment for severe COVID-19, with some published data suggesting reduced inflammatory markers and improved outcomes in certain patient populations. This is not the same as a Phase III trial demonstrating efficacy — the studies were often small and conducted under emergency conditions — but it generated enough signal to accelerate interest in Tα1 in post-infectious and immune-dysregulation contexts.

Thymalin is a polypeptide complex extracted from thymic tissue, developed and studied extensively by Khavinson and colleagues in Russia. Like Cortexin (its brain-tissue analog), Thymalin is a glandular extract rather than a single defined peptide — it contains a mixture of thymic regulatory peptides. It has been used clinically in Russia for decades in elderly patients and in post-infection recovery contexts, and the Russian clinical literature suggests effects on immune cell populations, inflammatory markers, and even longevity outcomes in older adults with some specificity of evidence. The evidence standard is not equivalent to FDA-trial quality, but Thymalin's clinical use history in Russia is substantial. Thymogen (Glu-Trp) is a dipeptide fragment developed from Thymalin research, representing the distillation of activity into a smaller defined molecule. Crystagen (Lys-Glu-Asp-Gly) is another defined peptide from this tradition. These shorter peptides are at earlier stages of independent clinical validation, though they remain in use in clinical contexts, particularly internationally.

Anti-inflammatory peptides form a distinct category within the immune landscape. KPV — the tripeptide Lys-Pro-Val — is a fragment of alpha-melanocyte-stimulating hormone (α-MSH) that has been studied for anti-inflammatory activity, particularly in gut-related immune contexts. Its mechanism involves inhibition of NF-κB, a central transcription factor in inflammatory signaling — NF-κB controls expression of many pro-inflammatory cytokines, and its downregulation reduces systemic inflammatory tone. KPV has also been studied for antimicrobial activity: research has explored its effects against certain bacteria and fungi, making it a compound with dual relevance in infected and inflamed tissue contexts.

VIP — vasoactive intestinal peptide — is a neuropeptide produced throughout the body: in the gut, lungs, and central nervous system. Its immune functions include induction of regulatory T cells (Tregs), suppression of pro-inflammatory Th1 and Th17 responses, and broad anti-inflammatory signaling. VIP is particularly interesting in the chronic illness space because it sits at the intersection of the nervous system, the gut, and immune regulation — the gut-brain-immune axis that has become increasingly central to understanding chronic dysregulation. In the context of Chronic Inflammatory Response Syndrome (CIRS), VIP has been researched and used clinically, particularly by practitioners following the Shoemaker protocol, in patients with mold-related illness and multi-system inflammatory conditions. The evidence base for VIP in these specific contexts is observational and practitioner-experience-based rather than large randomized trial-based, but clinical interest is substantial.

BPC-157 appears in the immune context because of its systemic anti-inflammatory properties and its effects on the autonomic nervous system, which has significant immune regulatory functions. The vagal nerve is a major conduit of anti-inflammatory signaling — vagal stimulation triggers acetylcholine release that suppresses macrophage inflammatory activity. BPC-157 has been proposed to modulate vagal tone, and its anti-inflammatory effects across multiple tissue types may be partly mediated through this pathway. The research is primarily preclinical; BPC-157's immune-relevant properties are secondary to its primary research in tissue repair and gut healing.

LL-37 is a cathelicidin — an antimicrobial peptide produced naturally by immune cells, particularly neutrophils and epithelial cells, as a front-line defense against pathogens. It's part of the innate immune system's direct antimicrobial arsenal, capable of disrupting bacterial and fungal membranes and reducing viral replication in cell culture studies. LL-37 also has immunomodulatory properties beyond direct killing: it recruits immune cells to sites of infection, modulates inflammatory responses, and has been studied for activity against biofilm-forming bacteria. Research into synthetic or compounded LL-37 for clinical use is early stage, but the compound generates interest particularly in the context of chronic or recalcitrant infections where conventional antibiotics haven't provided full resolution.

The intersection of peptides with specific chronic illness frameworks deserves specific attention. Long COVID — the post-acute sequelae of SARS-CoV-2 infection — has generated intense interest in immune-modulating peptides, particularly Tα1 and VIP, because many long COVID presentations appear to involve persistent immune dysregulation, viral persistence, or reactivation of latent viruses. Mast cell activation syndrome (MCAS), which involves dysregulated degranulation of mast cells with downstream systemic effects, has created clinical interest in anti-inflammatory peptides because conventional mast cell-stabilizing medications don't work for everyone. Chronic Lyme disease, post-Lyme syndrome, and tick-borne illness contexts represent another area where practitioners have explored immune-modulating peptides, particularly Tα1 and VIP, though the evidence in these specific conditions is largely clinical-observation-based.

The autoimmune caveat is one of the most important distinctions in this entire conversation. "Immune support" is not a monolithic concept. For someone with recurrent infections or a recovering immune system, supporting immune activation and Th1 responses may be appropriate. For someone with an autoimmune condition — where the immune system is already over-activated against self-tissue — the same activation is potentially harmful. Tα1, despite its modulating rather than simply stimulating profile, has effects that include Th1 amplification. For conditions where Th1 over-activity is part of the pathology — certain autoimmune diseases, some forms of lupus, some rheumatological conditions — immune-activating peptides require careful evaluation rather than protocol-based use. Immune modulation is not immune stimulation, but the difference is context-dependent and clinically significant.

The foundational context for immune function is less glamorous than any compound in this landscape and significantly more evidence-supported. Sleep is immunologically essential: the cytokine profiles that coordinate immune memory consolidation and pathogen defense are produced during sleep, and chronic sleep deprivation produces measurable immune suppression. Vitamin D deficiency is one of the most common nutritional deficiencies in the modern world and has direct effects on T-cell function, cathelicidin expression (including natural LL-37), and inflammatory regulation. Gut microbiome diversity is intimately connected to immune function — the gut-associated lymphoid tissue constitutes a major fraction of the immune system, and dysbiosis impairs immune calibration. Nutritional adequacy — zinc, vitamin C, protein status — matters for basic immune competence in ways that are often underestimated.

Chronic immune dysregulation is a signal that requires evaluation, not protocol-shopping. The pattern of recurrent infections, post-infectious syndromes, or multi-system inflammatory presentations can represent many different underlying mechanisms — viral persistence, autoimmune activation, MCAS, mold-related illness, mitochondrial dysfunction, thyroid pathology, nutritional deficiency. Identifying which mechanism is actually operating is the work that makes any subsequent intervention meaningful. A provider with expertise in immune dysfunction — not just general peptide prescribing, but genuine understanding of immune pathophysiology — is the appropriate starting point. The peptides described here are adjunctive in legitimate clinical contexts, not substitutes for that evaluation.